Cite

1. SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PROGRAM. Cancer Stat Facts: Pancreatic Cancer. 2019. Accessed from <www.seer.cancer.gov> on 11/30/2019.Search in Google Scholar

2. MCGUIGAN A., KELLY P., TURKINGTON, RC., JONES C., COLEMAN HG., MCCAIN RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43):4846–4861.10.3748/wjg.v24.i43.4846625092430487695Search in Google Scholar

3. MORRISON AH., BRYNE KT., VONDERHEIDE, RH. Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer 2018; 4(6):418–428.10.1016/j.trecan.2018.04.001602893529860986Search in Google Scholar

4. LEWIS A., LI D., WILLIAMS J., SINGH, G. Pancreatic Neuroendocrine Tumors: State-of-the-Art Diagnosis and Management. Oncology (Williston Park) 2017; 31(10):e1-e12.Search in Google Scholar

5. HAEBERLE L., ESPOSITO I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 2019; 4(50):eCollection.10.21037/tgh.2019.06.02662434731304427Search in Google Scholar

6. ABRAMSON MA., JAZAG A., VAN DER ZEE JA., WHANG EE. The molecular biology of pancreatic cancer. Gastrointest Cancer Res. 2007; 1(4):S7–S12.Search in Google Scholar

7. EGAWA S., TOMA H., OHIGASHI H., OKUSAKA T., NAKAO A., HATORI T., et al. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas 2012; 41(7):985–992.10.1097/MPA.0b013e318258055c22750974Search in Google Scholar

8. PATRA KC., BARDEESY N., MIZUKAMAI Y. Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. Clin Transl Gastroenterol. 2017; 8(4):e86.10.1038/ctg.2017.3541589928383565Search in Google Scholar

9. MINO-KENUDSON M., FERNANDEZ-DEL CASTILLO C., BAB Y., VALSANGKAR NP., LISS AS., HSU M., et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 2011; 60(12):1712–1720.10.1136/gut.2010.232272380608521508421Search in Google Scholar

10. TANAKA M., FERNANDEZ-DEL CASTILLO C., KAMISAWA T., JANG JY., LEVY P., OHTSUKA T., et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017; 17(5):738–753.10.1016/j.pan.2017.07.00728735806Search in Google Scholar

11. FISCHER CG., BELEVA GUTHRIE V., BRAXTON AM., ZHENG L., WANG P., SONG, Q. et al. Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations. Gastroenterology 2019; 157(4):1123–1137.10.1053/j.gastro.2019.06.001675695031175866Search in Google Scholar

12. LEVINK I., BRUNO MJ., CAHEN DL. Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives. Curr Treat Options Gastroenterol. 2018; 16(3):316–332.10.1007/s11938-018-0190-2615357030196428Search in Google Scholar

13. NAVEED S., QARI H., BANDAY T., ALTAF A., PARA M. Mucinous Cystic Neoplasms of Pancreas. Gastroenterology Res 2014; 7(2):44–50.10.14740/gr600e505107427785269Search in Google Scholar

14. ZAMBONI G., SCARPA A., BOGINA G., IACONO C., BASSI C., TALAMINI G., SESSA F. et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol. 1999; 23(4):410–422.10.1097/00000478-199904000-00005Search in Google Scholar

15. KOMMALAPATI A., TELLA SH., GOYAL G., MA WW., MAHIPAL, A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel) 2018; 10(1):E24.10.3390/cancers10010024Search in Google Scholar

16. BRAY F., FERLAY J., SOERJOMATARAM I., SIEGEL RL., TORRE L., JEMAL A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018; 68(6):394–424.10.3322/caac.21492Search in Google Scholar

17. INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. Estimated number of deaths from 2018 to 2040, all cancers, both sexes, all ages. Accessed from <gco.iacr.fr/tomorrow>on 3/2/2020.Search in Google Scholar

18. MIDHA S., CHAWLA S., GARG PK. Modifiable and non-modifiable risk factors for pancreatic cancer: A review. Cancer Lett 2016; 381(1):269–277.10.1016/j.canlet.2016.07.022Search in Google Scholar

19. RAIMONDI S., LOWENFELS AB., MORSELLI-LABATE AM., MAISONNEUVE P., PEZZILLI R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010; 24(3):349–358.10.1016/j.bpg.2010.02.007Search in Google Scholar

20. WHITTEMORE AS., PAFFENBARGER RS. JR, ANDERSON K., HALPERN J. Early precursors of pancreatic cancer in college men. J Chronic Dis 1983; 36(3):251–256.10.1016/0021-9681(83)90059-0Search in Google Scholar

21. TRANAH GH., HOLLEY EA., WANG F., BRACCI PM. Cigarette, cigar and pipe smoking, passive smoke exposure, and risk of pancreatic cancer: a population-based study in the San Francisco Bay Area. BMC Cancer 2011; 11:138.10.1186/1471-2407-11-138309432521496267Search in Google Scholar

22. ZHENG J., GUINTER MA., MERCHANT AT., WIRTH MD., ZHANG J., STOLZENBERG-SOLOMON RZ. et al. Dietary patterns and risk of pancreatic cancer: a systematic review. Nutr Rev. 2017; 75(11):883–908.10.1093/nutrit/nux038591445429025004Search in Google Scholar

23. LI D. Diabetes and pancreatic cancer. Mol Carcinog. 2012; 51(1):64–74.10.1002/mc.20771323879622162232Search in Google Scholar

24. SHARMA A., KANDLAKUNTA H., NAGPAL SJS., FENG Z., HOOS W., PETERSEN GM. et al. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterol. 2018; 155(3):730–739.10.1053/j.gastro.2018.05.023612078529775599Search in Google Scholar

25. KIRKEGARD J., CRONIN-FENTON D., HEIDE-JORGENSEN U., MORTENSEN FV. Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-Cohort Study in Denmark. Gastroenterol. 2018; 154(6):1729–1736.10.1053/j.gastro.2018.02.01129432727Search in Google Scholar

26. DOBBINS M., DECORBY K., CHOI BCK. The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011. ISRN Prev Med. 2013;eCollection 2013.10.5402/2013/680536406285724977095Search in Google Scholar

27. BERRINGTON DE GONZALEZ A., SWEETLAND S., SPENCER E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003; 89(3):519–523.10.1038/sj.bjc.6601140239438312888824Search in Google Scholar

28. BEHRENS G., JOCHEM C., SCHMID D., KEIMLING M., RICCI C., LEITZMANN, MF. Physical activity and risk of pancreatic cancer: a systematic review and meta-analysis. Eur J Epidemiol. 2015; 30(4):279–298.10.1007/s10654-015-0014-925773752Search in Google Scholar

29. BRACCI PM. Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog. 2012; 51(1):53–63.10.1002/mc.20778334811722162231Search in Google Scholar

30. YEO TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015; 42(1):8–18.10.1053/j.seminoncol.2014.12.00225726048Search in Google Scholar

31. NAUDIN, S., VIALLON V., HASHIM D., FREISLING H., JENAB M., WEIDERPASS, E. Healthy lifestyle and the risk of pancreatic cancer in the EPIC study. Eur J Epidemiol 2019;Epub ahead of print.10.1007/s10654-019-00559-6711613631564045Search in Google Scholar

32. PETERSEN GM. Familial pancreatic cancer. Semin Oncol. 2916; 43(5):548–553.10.1053/j.seminoncol.2016.09.002523408527899186Search in Google Scholar

33. AMUNDADOTTIR LT. Pancreatic Cancer Genetics. Int J Biol Sci. 2016; 12(3):314–325.10.7150/ijbs.15001475316026929738Search in Google Scholar

34. SOURA E., ELIADES PJ., SHANNON K., STRATIGOS AJ., TSAO H. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol. 2016; 74(3):395–40.10.1016/j.jaad.2015.08.038476110526892650Search in Google Scholar

35. KASTRINOS F., MUKHERJEE B., TAYOB N., WANG F., SPARR J., RAYMOND VM. et al. Risk of pancreatic cancer in families with Lynch syndrome. J Am Med Assoc. 2009; 302(16):1790–1795.10.1001/jama.2009.1529409162419861671Search in Google Scholar

36. RUIJS MWG., VERHOEF S., ROOKUS MA., PRUNTEL R., VAN DER HOUT AH., HOGERVORST FBL. et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010; 47(6):421–428.10.1136/jmg.2009.07342920522432Search in Google Scholar

37. GIARDIELLO FM., OFFERHAUS GJ., LEE DH., KRUSH AJ., BOOKER SV., KELLEY NC. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34(10):1394–1396.10.1136/gut.34.10.139413745488244108Search in Google Scholar

38. THOMPSON D., DUEDAL A., KIRNER J., MCGUFFOG L., LAST J., REIMAN A. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005; 97(11):813–822.10.1093/jnci/dji14115928302Search in Google Scholar

39. BORECKA M., ZEMANKOVA P., VOCKA M., SOUCEK P., SOUKUPOVA J., KLEIBLOVA P. et al. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic. Cancer Genet. 2016; 209(5):199–204.10.1016/j.cancergen.2016.03.00327106063Search in Google Scholar

40. BRUNE KA., LAU B., PALMISANO E., CANTO M., GOGGINS MG., HRUBAN RH. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 2010; 102(2):119–126.10.1093/jnci/djp466280834620068195Search in Google Scholar

41. JACOBS EJ., CHANOCK SJ., FUCHS CS., LACROIX A., MCWILLIAMS RR., STEPLOWSKI E. et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer 2010; 127(6):1421–1428.10.1002/ijc.25148292693920049842Search in Google Scholar

42. SHIRTS BH., BURT RW., MULVIHILL SJ., CANNON-ALBRIGHT LA. A population-based description of familial clustering of pancreatic cancer. Clin Gastroenterol Hepatol. 2010; 8(9):812–816.10.1016/j.cgh.2010.05.01220570637Search in Google Scholar

43. WOLPIN BM., CHAN AT., HARTGE P., CHANOCK SJ., KRAFT P., HUNTER DJ. et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009; 101(6):424–431.10.1093/jnci/djp020265709519276450Search in Google Scholar

44. HUANG BZ., STRAM DO., LE MARCHAND L., HAIMAN CA., WILKENS LR., PANDOL SL. Interethnic differences in pancreatic cancer incidence and risk factors: The Multiethnic Cohort. Cancer Med. 2019; 8(7):3592–360.10.1002/cam4.2209660157931066497Search in Google Scholar

45. GOGGINS M., OVERBEEK KA., BRAND R., SYNGAL S., DEL CHIARO M., BARTSCH, DK. et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69(1):7–17.10.1136/gutjnl-2019-319352729500531672839Search in Google Scholar

46. STOFFEL EM., MCKERNIN SE., BRAND R., CANTO M., GOGGINS M., MORAVEK C. et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2019; 37(2):153–164.10.1200/JCO.18.0148930457921Search in Google Scholar

47. TEMPERO MA. NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019; 17(5.5):603–605.10.6004/jnccn.2018.004329784737Search in Google Scholar

48. HENRIKSON NB., AIELLO BOWLES EJ., BLASI PR., MORRISON CC., NGUYEN M., PILLARISETTY VG. Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. J Amer Med Assoc. 2019; 322(5):445–454.10.1001/jama.2019.619031386140Search in Google Scholar

49. JOERGENSEN MT., GERDES AM., SORENSEN J., SCHAFFALITZKY DE MUCKADELL O., MORTENSEN MB. Is screening for pancreatic cancer in high-risk groups cost-effective? – Experience from a Danish national screening program. Pancreatol. 2016; 16(4):584–592.10.1016/j.pan.2016.03.01327090585Search in Google Scholar

50. CANTO MI., HRUBAN RH., FISHMAN EK., KAMEL IR., SCHULICK R., ZHANG Z. et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterol. 2012; 142(4):796–804.10.1053/j.gastro.2012.01.005332106822245846Search in Google Scholar

51. YOSHIDA T., YAMASHITA Y., KITANO M. Endoscopic Ultrasound for Early Diagnosis of Pancreatic Cancer. Diagnostics (Basel) 2019; 9(3):E81.10.3390/diagnostics9030081678771031344904Search in Google Scholar

52. HATA T., DAL MOLIN M., HONG SM., TAMURA K., SUENAGA M., YU J. et al. Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers. Clin Cancer Res. 2017;23(14):3935–3944.10.1158/1078-0432.CCR-16-2244551155528148542Search in Google Scholar

53. HART PA., TOPAZIAN M., RAIMONDO M., CRUZ-MONSERRATE Z., FISHER WE., LESINSKI GB. et al. Endoscopic Pancreas Fluid Collection: Methods and Relevance for Clinical Care and Translational Science. Am J Gastroenterol. 2016; 111(9):1258–1266.10.1038/ajg.2016.297556800327481304Search in Google Scholar

54. SHIN EJ., TOPAZIAN M., GOGGINA MG., SYNGAL S., SALTZMAN JR., LEE JH. Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study. Gastrointest Endosc. 2015; 82(5):812–818.10.1016/j.gie.2015.02.028460923425930097Search in Google Scholar

55. CAZACU IM., LUZURIAGA CHAVEZ AA., SAFTOIU A., VILMANN P., BHUTANI MS. A quarter century of EUS-FNA: Progress, milestones, and future directions. Endosc Ultrasound 2018; 7(3):141–160.10.4103/eus.eus_19_18603270529941723Search in Google Scholar

56. KITANO M., YOSHIDA T., ITONAGA M., TAMURA T., HATAMARU K., YAMASHITA Y. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J Gastroenterol. 2019; 54(1):19–32.10.1007/s00535-018-1519-2631498530406288Search in Google Scholar

57. MCALLISTER F., MONTIEL MF., UBEROI GS., UBEROI AS., MAITRA A., BHUTANI MS. Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer. Gastroenterol Hepatol. 2017; 13(5):268–275.Search in Google Scholar

58. TUMMALA P., JUNAIDI O., AGARWAL B. Imaging of pancreatic cancer: An overview. J Gastrointest Oncol. 2011; 2(3):168–174.Search in Google Scholar

59. KANG HJ., LEE JM., JOO I., HUR BY., JEON JH., JANG JY. et al. Assessment of Malignant Potential in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Comparison between Multidetector CT and MR Imaging with MR Cholangiopancreatography. Radiol. 2016; 279(1):128–139.10.1148/radiol.201515021726517448Search in Google Scholar

60. ZHANG L., SANAGAPALLI S., STOITA A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018; 24(19):2047–2060.10.3748/wjg.v24.i19.2047596081129785074Search in Google Scholar

61. ASHIDA R., TANAKA S., YAMANAKA H., OKAGAKI S., NAKAO K., FUKUDA J. et al. The Role of Transabdominal Ultrasound in the Diagnosis of Early Stage Pancreatic Cancer: Review and Single-Center Experience. Diagnostics (Basel) 2018; 9(1):2.10.3390/diagnostics9010002646879730587766Search in Google Scholar

62. CANTO MI., HARINCK F., HRUBAN RH., OFFERHAUS GJ., POLEY JW., KAMEL I. et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62(3):339–347.10.1136/gutjnl-2012-303108358549223135763Search in Google Scholar

63. PORUK KE., FIRPO MA., ADLER DG., MULVIHILL SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg. 2012; 257(1):17–26.10.1097/SLA.0b013e31825ffbfbSearch in Google Scholar

64. ELTA GH., ENESTVEDT BK., SAUER BG., LENNON AM. ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol. 2018; 113(4):464–479.10.1038/ajg.2018.1429485131Search in Google Scholar

65. KELLY FF., IHAB RK., JEANNE MH., HINA AT., MUSTAFA RB., VICTORIA C. et al. ACR Appropriateness Criteria: Pancreatic Cyst. Accessed from <https://acsearch.acr.org/docs/3127236/Narrative/> on 1/22/2020.Search in Google Scholar

66. PORUK KE., GAY DZ., BROWN K., MULVIHILL JD., BOUCHER KM., SCAIFE CL. et al. The clinical utility of CA 19–9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013; 13(3):340–351.10.2174/1566524011313030003Search in Google Scholar

67. MENG Q., SHI S., LIANG C., LIANG D., XU W., JI S. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017; 10:4591–4598.10.2147/OTT.S145708560808228979147Search in Google Scholar

68. COSTACHE MI., COSTACHE CA., DUMITRESCU CI., TICA AA., POPESCU M., BALUTA EA. et al. Which is the Best Imaging Method in Pancreatic Adenocarcinoma Diagnosis and Staging – CT, MRI or EUS? Curr Health Sci J. 2017; 43(2):132–136.Search in Google Scholar

69. TOFT J., HADDEN WJ., LAURENCE JM., LAM V., YUEN L., JANSSEN A. et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol. 2017; 92:17–23.10.1016/j.ejrad.2017.04.00928624015Search in Google Scholar

70. ZHANG H., ZHU J., KE F., WENG M., WU X., LI M. et al. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015; 2015:497942.10.1155/2015/497942456975826448940Search in Google Scholar

71. SHRIKHANDE SV., BARRETO SG., GOEL M., ARYA S. Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature. HPB (Oxford) 2012; 14(10):658–668.10.1111/j.1477-2574.2012.00508.x346137122954001Search in Google Scholar

72. JUDY MK., GANESH K., PRAVEEN KJ., PRASAD H., CHIDANANDA M., ARUN K. A Comparative Evaluation of USG and MRCP Findings in Biliary and Pancreatic Pathologies. Int J Contemp Med Res. 2017; 4(1):212–215.Search in Google Scholar

73. MICHL P., PAULS S., GRESS TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006; 20(2):227–251.10.1016/j.bpg.2005.10.00516549326Search in Google Scholar

74. ELOUBEIDI MA., VARADARAJULU S., DESAI S., SHIRLEY R., HESLIN MJ., MEHRA M. et al. A prospective evaluation of an algorithm incorporating routine preoperative endoscopic ultrasound-guided fine needle aspiration in suspected pancreatic cancer. J Gastrointest Surg. 2007; 11(7):813–819.10.1007/s11605-007-0151-x17440790Search in Google Scholar

75. OKASHA HH., NAGA MI., ESMAT S., NAGUIB M., HASSANEIN M., HASSANI M. et al. Endoscopic Ultrasound-Guided Fine Needle Aspiration versus Percutaneous Ultrasound-Guided Fine Needle Aspiration in Diagnosis of Focal Pancreatic Masses. Endosc Ultrasound 2014; 2(4):190–193.10.4103/2303-9027.121239Search in Google Scholar

76. WANG XY., YANG F., JIN C., FU DL. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol. 2014; 20(42):15580–15589.10.3748/wjg.v20.i42.15580422952225400441Search in Google Scholar

77. BRONSTEIN YL., LOYER EM., KAUR H., CHOI H., DAVID C., DUBROW RA. et al. Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol. 2004; 182(3):619–623.10.2214/ajr.182.3.182061914975959Search in Google Scholar

78. LEGMANN P., VIGNAUX O., DOUSSET B., BARAZA AJ., PALAZZO L., DUMONTIER, I. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol. 1998; 170(5):1315–1322.10.2214/ajr.170.5.95746099574609Search in Google Scholar

79. WONG JC., LU DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008; 6(12):1301–1308.10.1016/j.cgh.2008.09.01418948228Search in Google Scholar

80. SHEN YN., BAI XL., LI GG., LIANG TB. Review of radiological classifications of pancreatic cancer with peripancreatic vessel invasion: are new grading criteria required? Cancer Imag. 2017; 17(1):14.10.1186/s40644-017-0115-7542008828477615Search in Google Scholar

81. TANAKA S., KITAMRA T., YAMAMOTO K., FUJIKAWA S., IMAOKA T., NISHIKAWA S. et al. Evaluation of routine sonography for early detection of pancreatic cancer. Jpn J Clin Oncol. 1996; 26(6):422–427.10.1093/oxfordjournals.jjco.a0232599001347Search in Google Scholar

82. MARINGHINI A., CIAMBRA M., RAIMONDO M., BACCELLIERE P., GRASSO R. DARDANONI G. Clinical presentation and ultrasonography in the diagnosis of pancreatic cancer. Pancreas 1993; 8(2):146–150.10.1097/00006676-199303000-000028460088Search in Google Scholar

83. CONRAD C., FERNANDEZ-DEL CASTILLO C. Preoperative evaluation and management of the pancreatic head mass. J Surg Oncol. 2013; 107(1):23–32.10.1002/jso.2316522674403Search in Google Scholar

84. GOONETILLEKE KS., SIRIWARDENA AK. Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007; 33(3):266–270.10.1016/j.ejso.2006.10.00417097848Search in Google Scholar

85. CHU LC., PARK S., KAWAMOTO S., WANG Y., ZHOU Y., SHEN W. Application of Deep Learning to Pancreatic Cancer Detection: Lessons Learned From Our Initial Experience. J Am Coll Radiol. 2019; 16(9B):1338–1342.10.1016/j.jacr.2019.05.03431492412Search in Google Scholar

86. CAZACU IM., UDRISTOUI A., GRUIONU LG., IACOB A., GRUIONU G., SAFTOIU A. Artificial intelligence in pancreatic cancer: Toward precision diagnosis. Endosc Ultrasound 2019; 8(6):357–359.10.4103/eus.eus_76_19692714531854344Search in Google Scholar

87. OZKAN M., CAKIROGLU M., KOCAMAN O., KURT M., YILMAZ B., CAN G. et al. Age-based computer-aided diagnosis approach for pancreatic cancer on endoscopic ultrasound images. Endosc Ultrasound 2016; 5(2):101–107.10.4103/2303-9027.180473485078827080608Search in Google Scholar

88. ZHU M., XU C., YU J., WU Y., LI C., ZHANG M. et al. Differentiation of pancreatic cancer and chronic pancreatitis using computer-aided diagnosis of endoscopic ultrasound (EUS) images: a diagnostic test. PLoS One 8 2013; 8(5):e63820.10.1371/journal.pone.0063820366038223704940Search in Google Scholar

89. MUHAMMAD W., HART GR., NARTOWT B., FARRELL JJ., JOHUNG K., LIANG Y. et al. ancreatic Cancer Prediction Through an Artificial Neural Network. Front In Art Intel. 2019; 2(2):1–10.10.3389/frai.2019.00002Search in Google Scholar

90. HASAN S., JACOB R., MANNE U., PALURI, R. Advances in pancreatic cancer biomarkers. Oncol Rev. 2019;13(1):410.10.4081/oncol.2019.410647800631044028Search in Google Scholar

91. DUAN L., HU XQ., FENG DY., LEI SY., HU GH. GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer. Asian J Surg. 2013; 36(1):7–12.10.1016/j.asjsur.2012.08.00123270819Search in Google Scholar

92. MELO SA., LUECKE LB., KAHLERT C., FERNANDEZ AF., GAMMON ST., KAYE J. et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015; 523(7559):177–182.10.1038/nature14581482569826106858Search in Google Scholar

93. LIU D., CHANG CH., GOLD DV., GOLDENBERG DM. Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer. Oncotarget 2015; 6(6):4274–4285.10.18632/oncotarget.2760441418925595893Search in Google Scholar

94. DEBERNARDI S., MASSAT NJ., RADON TP., SANGARALINGAM A., BANISSI A., ENNIS DP. et al. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. Am J Cancer Res. 2015; 5(11):3455–3466.Search in Google Scholar

95. CRISTIANO S., LEAL A., PHALLEN J., FIKSEL J., ADLEFF V., BRUHM DC. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 2019; 570(7761):385–389.10.1038/s41586-019-1272-6677425231142840Search in Google Scholar

96. LAN B., ZENG S., GRUTZMANN R., PILARSKY C. The Role of Exosomes in Pancreatic Cancer. Int J Mol Sci. 2019; 20(18):E4332.10.3390/ijms20184332677078131487880Search in Google Scholar

eISSN:
2501-062X
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, other, Cardiology, Gastroenterology, Rheumatology